Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Liquidia Co. (NASDAQ:LQDA) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $24.00.

A number of equities research analysts recently weighed in on LQDA shares. BTIG Research cut their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. Lifesci Capital began coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Bank of America lowered their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Finally, Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock.

Liquidia Price Performance

Shares of Liquidia stock opened at $11.03 on Tuesday. Liquidia has a 1-year low of $7.34 and a 1-year high of $16.99. The business’s fifty day moving average price is $10.93 and its two-hundred day moving average price is $11.23. The company has a market capitalization of $933.55 million, a P/E ratio of -6.77 and a beta of 0.22.

Insider Activity

In related news, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the sale, the general counsel now owns 486,048 shares in the company, valued at approximately $5,399,993.28. This represents a 0.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,007 shares of company stock worth $245,780. Insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Hedge funds have recently modified their holdings of the business. Barclays PLC increased its holdings in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after purchasing an additional 72,591 shares during the period. Anson Funds Management LP purchased a new position in Liquidia during the third quarter valued at approximately $1,764,000. XTX Topco Ltd purchased a new position in Liquidia during the third quarter valued at approximately $323,000. Wellington Management Group LLP increased its stake in Liquidia by 12.5% in the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock valued at $1,799,000 after buying an additional 19,932 shares during the period. Finally, Whitefort Capital Management LP lifted its position in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).